| Literature DB >> 34652447 |
Tomer Gazit1, Michal Gutman1, Alexis L Beatty2.
Abstract
Importance: It is unclear whether mobile technology hypertension self-management programs are associated with blood pressure (BP) control. Objective: To examine whether engagement with a hypertension self-management program with a BP monitor and connected smartphone application with clinically based digital coaching was associated with BP control during a follow-up period of as long as 3 years. Design, Setting, and Participants: This cohort study enrolled US adults with elevated BP or hypertension between January 1, 2015, and July 1, 2020. The hypertension self-management program was provided through the participant's (or their spouse's) employer health plan. Exposures: Program engagement, defined by average number of application sessions. Main Outcomes and Measures: Systolic and diastolic BP measured by a US Food and Drug Administration-cleared BP monitor, with categories defined as normal (systolic BP, <120 mm Hg), elevated (systolic BP, 120-129 mm Hg), stage 1 hypertension (systolic BP, 130-139 mm Hg), and stage 2 hypertension (systolic BP ≥140 mm Hg). Other measures included age, gender, depression, anxiety, diabetes, high cholesterol, smoking, geographic region, area deprivation index, self-reported weight, and device-measured physical activity (steps per day).Entities:
Mesh:
Year: 2021 PMID: 34652447 PMCID: PMC8520130 DOI: 10.1001/jamanetworkopen.2021.27008
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Participant Characteristics
| Characteristic | Participants, No./total No. (%) by engagement | |||
|---|---|---|---|---|
| All (N = 28 189) | Low (n = 8199) | Medium (n = 12 417) | High (n = 7573) | |
| Age, median (IQR), y | 51 (43-58) | 48 (39-56) | 50 (42-57) | 53 (47-59) |
| Sex | ||||
| Women | 9424/23 326 (40.4) | 2821/6547 (43.0) | 4262/10 416 (40.0) | 2341/6447 (36.0) |
| Men | 13 902/23 326 (59.6) | 3726/6547 (57.0) | 6154/10 416 (60.0) | 4106/6447 (64.0) |
| Comorbidities | ||||
| Depression | 1624/28 189 (5.8) | 531/8199 (6.5) | 714/12 417 (5.8) | 379/7573 (5.0) |
| Anxiety | 2899/28 189 (10.3) | 922/8199 (11.3) | 1306/12 417 (10.5) | 671/7573 (8.9) |
| Diabetes | 1340/28 189 (4.8) | 376/8199 (4.6) | 493/12 417 (4.0) | 471/7573 (6.2) |
| High cholesterol | 5191/28 189 (18.4) | 1358/8199 (17.7) | 2195/12 417 (17.7) | 1638/7573 (21.6) |
| Smoking | 189/3244 (6.2) | 57/782 (7.3) | 80/1329 (6.0) | 52/1133 (4.6) |
| ADI, median (IQR), percentile | 50 (39-59) | 51 (39-59) | 50 (39-59) | 50 (38-59) |
| Lowest quintile ADI neighborhood | 794/25 284 (3.2) | 247/7376 (3.3) | 339/11 160 (3.0) | 208/6748 (3.1) |
| Region of country | ||||
| West | 2833/25 285 (11.2) | 733/7376 (9.9) | 1201/11 160 (10.8) | 899/7284 (12.3) |
| Midwest | 6941/25 285 (27.5) | 2196/7376 (29.8) | 3299/11 160 (29.6) | 1446/7284 (19.9) |
| South | 12 937/25 285 (51.2) | 3787/7376 (51.3) | 5573/11 160 (50.0) | 4112/7284 (56.5) |
| Northeast | 2574/25 285 (10.2) | 660/7376 (9.0) | 1087/11 160 (9.7) | 827/7284 (11.3) |
| Systolic blood pressure in the first week, median (IQR), mm Hg | 129.5 (120.5-139.6) | 130.0 (120.7-141.0) | 129.6 (120.6-139.5) | 128.6 (120.0-138.2) |
| Diastolic blood pressure in the first week, median (IQR), mm Hg | 81.7 (75.7-88.4) | 82.0 (75.6-89.0) | 81.9 (75.9-88.4) | 81.0 (75.4-87.5) |
Abbreviation: ADI, area deprivation index.
Engagement was categorized by the frequency with which the participant engaged with the application.
Age data were available for a total of 22 420 participants: 6336 in the low-engagement group, 9792 in the medium-engagement group, and 6292 in the high-engagement group.
ADI data were available for 25 284 total participants: 7376 in the low-engagement group, 11 160 in the medium-engagement group, and 6748 in the high-engagement group.
Application Use
| Use measure | Engagement frequency, median (IQR) | |||
|---|---|---|---|---|
| All | Engagement Group | |||
| Low | Medium | High | ||
| Weeks of use | 25 (7-57) | 9 (2-30) | 23 (8-49) | 59 (28-101) |
| Weeks of use for participants enrolled before Oct 2019 | 41 (9-79) | 10 (2-42) | 34 (8-67) | 69 (37-110) |
| Use/wk | 1.8 (0.9-3.6) | 1.3 (0.6-2.8) | 1.7 (0.9-3.2) | 2.8 (1.5-5.3) |
Engagement was categorized by the frequency with which the participant engaged with the application.
Since participants enrolled in the program at different times during the study period, duration of follow-up was not the same for all participants and not all participants provided data for all time points.
Figure. Blood Pressure Change Over Time by Baseline Blood Pressure
Normal blood pressure was defined as systolic blood pressure of less than 120 mm Hg; elevated blood pressure, systolic blood pressure of 120 to 129 mm Hg; stage 1 hypertension, systolic blood pressure of 130 to 139 mm Hg, and stage 2 hypertension, systolic blood pressure of 140 mm Hg or greater. Shaded areas indicate 95% CIs.
BP Reduction Over Time by Initial BP Category
| Time from enrollment | Included weeks | Participants, No. | Participants who reduced median systolic BP, No. (%) | Mean difference in systolic BP (SEM) | Mean difference in diastolic BP (SEM) |
|---|---|---|---|---|---|
| Elevated BP | |||||
| 2 wk | 1-2 | 3363 | 1705 (50.7) | –6.3 (0.1) | –3.0 (0.1) |
| 4 wk | 3-4 | 3006 | 1611 (53.6) | –6.9 (0.1) | –3.7 (0.1) |
| 6 wk | 5-6 | 2630 | 1428 (54.3) | –7.3 (0.1) | –3.9 (0.1) |
| 12 wk | 11-12 | 1797 | 1021 (56.8) | –8.4 (0.2) | –4.6 (0.2) |
| 26 wk | 24-27 | 1269 | 717 (56.5) | –8.2 (0.2) | –4.6 (0.2) |
| 1 y | 48-55 | 934 | 495 (53.0) | –7.9 (0.2) | –4.4 (0.2) |
| 2 y | 96-111 | 489 | 258 (52.8) | –7.5 (0.3) | –4.7 (0.3) |
| 3 y | 148-163 | 154 | 83 (53.7) | –7.2 (0.4) | –4.4 (0.6) |
| Stage 1 hypertension | |||||
| 2 wk | 1-2 | 3291 | 2047 (62.2) | –7.9 (0.1) | –3.5 (0.1) |
| 4 wk | 3-4 | 2869 | 1859 (64.8) | –8.8 (0.1) | –4.3 (0.1) |
| 6 wk | 5-6 | 2513 | 1654 (65.8) | –9.4 (0.1) | –4.6 (0.1) |
| 12 wk | 11-12 | 1788 | 1250 (69.9) | –10.3 (0.2) | –5.2 (0.2) |
| 26 wk | 24-27 | 1372 | 1002 (73.0) | –11.0 (0.2) | –5.6 (0.2) |
| 1 y | 48-55 | 966 | 673 (69.7) | –10.2 (0.2) | –5.4 (0.2) |
| 2 y | 96-111 | 436 | 318 (72.9) | –10.4 (0.3) | –5.9 (0.4) |
| 3 y | 148-163 | 131 | 99 (75.3) | –12.2 (0.7) | –6.8 (0.6) |
| Stage 2 hypertension | |||||
| 2 wk | 1-2 | 3757 | 2814 (74.9) | –12.9 (0.2) | –5.6 (0.1) |
| 4 wk | 3-4 | 3272 | 2585 (79.0) | –14.7 (0.2) | –7.0 (0.2) |
| 6 wk | 5-6 | 2917 | 2351 (80.6) | –15.7 (0.2) | –7.5 (0.2) |
| 12 wk | 11-12 | 2061 | 1748 (84.8) | –17.5 (0.3) | –8.7 (0.2) |
| 26 wk | 24-27 | 1630 | 1410 (86.5) | –19.0 (0.3) | –9.5 (0.3) |
| 1 y | 48-55 | 1074 | 920 (85.7) | –19.2 (0.4) | –9.6 (0.4) |
| 2 y | 96-111 | 419 | 370 (88.4) | –19.4 (0.6) | –10.1 (0.6) |
| 3 y | 148-163 | 108 | 91 (84.4) | –20.9 (1.7) | –11.6 (1.9) |
Abbreviations: BP, blood pressure; SEM, standard error of mean.
Number of participants at each time represents participants who had been enrolled in the program long enough to have reached that point and who had application activity during the weeks listed. Since participants enrolled in the program at different times during the study period, duration of follow-up was not the same for all participants and not all participants provided data for all time points.
Differences were calculated only in participants who reduced systolic BP.